Background. The recent joint International Society for Pharmacoeconomics and Outcomes Research / Society for Medical Decision Making Modeling Good Research
Practices Task Force emphasized the importance of conceptualizing and validating models. We report a new model of chronic obstructive pulmonary disease (COPD) (part of the Galaxy project) founded on a conceptual model, implemented using a novel linked-equation approach, and internally validated. Methods. An expert panel developed a conceptual model including causal relationships between disease attributes, progression, and final outcomes. Risk equations describing these relationships were estimated using data from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study, with costs estimated from the TOwards a Revolution in COPD Health (TORCH) study. Implementation as a linked-equation model enabled direct estimation of health service costs and quality-adjusted life years (QALYs) for COPD patients over their lifetimes. Internal validation compared 3 years of predicted cohort experience with ECLIPSE results. Results. At 3 years, the Galaxy COPD model predictions of annual exacerbation rate and annual decline in forced expiratory volume in 1 second fell within the ECLIPSE data confidence limits, although 3- year overall survival was outside the observed confidence limits. Projections of the risk equations over time permitted extrapolation to patient lifetimes. Averaging the predicted cost/QALY outcomes for the different patients within the ECLIPSE cohort gives an estimated lifetime cost of £25,214 (undiscounted)/£20,318 (discounted) and lifetime QALYs of 6.45 (undiscounted/5.24 [discounted]) per ECLIPSE patient.
Conclusions.
A new form of model for COPD was conceptualized, implemented, and internally validated, based on a series of linked equations using epidemiological data (ECLIPSE) and cost data (TORCH). This Galaxy model predicts COPD outcomes from treatment effects on disease attributes such as lung function, exacerbations, symptoms, or exercise capacity; further external validation is required. Key words: COPD; QALY; cost; risk; model (Med Decis Making 2017;37:469-480) C hronic obstructive pulmonary disease (COPD) is a respiratory disorder characterized by airflow obstruction, leading to shortness of breath, acute exacerbations, and death. 1 Globally, COPD is the fourth leading cause of death. 2 In England, more than 860,000 individuals were diagnosed with COPD in 2009-2010, corresponding to a prevalence of 1.6%. 3 However, it is estimated that most cases remain undiagnosed and that the true prevalence of COPD is much higher, potentially affecting more than 3 million people. 1 Smoking is the primary risk factor for developing COPD, and exposures to noxious fumes, dust, and gas are also risk factors. 4 The economic burden of COPD is high; it is one of the most costly inpatient conditions treated by the National Health Service in the United Kingdom, with an estimated direct cost of £810 to £930 million per year. 1 A number of models of COPD have been used for economic analysis for health technology assessment (HTA). Most of these are structured around disease ''states'' that are usually defined using threshold values of percent predicted forced expiratory volume in 1 second (FEV 1 ), adjusted for patients according to age, sex, and height. 5, 6 However, recent prognostic modeling has shown that other aspects of the disease, such as symptoms and exercise capacity, are also important factors for survival, [7] [8] [9] and clinical guidelines are beginning to acknowledge the multifaceted nature of COPD 2 (i.e., that there is inherent heterogeneity in health outcomes for COPD patients that depends on more than just FEV 1 ). 8 The Galaxy project was undertaken to develop a new disease/economic model for COPD, accounting for recent developments in the understanding of COPD as a multifaceted disease. The aim was to develop a model with sufficient flexibility to reflect different patient groups, based on an understanding of relationships between disease characteristics, risk factors, biomarkers, and surrogates, on relevant clinical outcomes and disease progression over time. This allows for a better capture of the inherent heterogeneity and corresponding adjustments made for different COPD patient populations, which facilitates comparisons of disease progression between different COPD subgroups. The development of the new Galaxy COPD model has adhered as closely as possible to best practice guidelines for medical decision modeling, 10 which emphasize the importance of conceptual modeling. 11 The modeling and analysis we report in this article were founded on a conceptual model designed by a panel of experts prior to data analysis 12 and a series of linked risk equations that were developed from the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) data set based on the relationships from the conceptual modeling exercise. 13 This article brings the previous work together in a cohesive whole and internally validates the model using the same data that were used to generate model parameters.
METHODS

Data Sources
The ECLIPSE study was a noninterventional, observational, multicenter, 3-year study designed to determine mechanisms of disease progression and identify biomarkers that could serve as end points to measure progression of COPD. 14 This study included 2164 patients with COPD, with an average age of 63.4 years, an average of 0.9 exacerbations in the year prior to study entry, and baseline percent predicted FEV 1 of 48.3%. Patients for whom full information on baseline characteristics was available (n = 1957) were included in the present model.
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Supplementary material for this article is available on the Medical Decision Making Web site at http://journals.sagepub.com/home/mdm. of 1.0 exacerbation in the year prior to study entry, and baseline percent predicted FEV 1 was 44.1%.
Patients included in the model had baseline characteristics that were slightly different from the original published studies, due to small amounts of missing information in the baseline covariates used in the modeling. However, there were no important differences between characteristics of the cohorts analyzed here and the original studies. Summary information for the analysis cohorts is given in the Supplemental Appendix A (available online) in Supplemental Table S1 .
Structure of the Model
The model described the important prognostic factors for COPD disease progression at baseline; the disease progression attributes that evolve over the lifetime of the model, such as exacerbations, lung function, exercise capacity, and symptoms; and the final outcomes of mortality, health-related quality of life (HRQoL), and health service resource use. In particular, lung function and exacerbations were assumed to affect each other in the conceptual model, with lung function affecting symptoms, symptoms affecting exacerbations, and all 3 of these attributes affecting exercise capacity. 12 These relationships from the final conceptual model were used as the basis for estimating a series of linked statistical equations using data from ECLIPSE, which formed the epidemiological foundation of the disease model. 13 The statistical equations were brought together to estimate the course of COPD for a patient cohort in terms of the disease progression attributes defined in the conceptual model through to final health outcomes of (quality-adjusted) life expectancy and health service cost. Observational data from ECLIPSE were used to estimate associations between disease progression attributes, together with mortality and HRQoL (measured by the St. George's Respiratory Questionnaire for COPD [SGRQ-C]), 16 while adjusting for prognostic baseline covariates. However, because ECLIPSE did not record health service resource use, the resource use equations were estimated using data from TORCH. Figure 1a illustrates the links between the statistical risk equations from the baseline prognostic variables through to the disease progression attributes of COPD 13 representing the relationships described in the conceptual model 12 above. Figure  1b shows the associations from the baseline covariates and the disease progression attributes through to the final health outcomes. The Galaxy COPD model starts with the baseline covariates recorded in ECLIPSE (Suppl . Table S1 ) and then builds on these by predicting how the baseline covariates affect the disease progression attributes of exacerbations, lung function, exercise capacity, and symptoms. Not all baseline variables were used in every equation, although all variables from Supplemental Table S1 were candidate covariates and appeared in at least one of the equations (see Exuzides and others 13 for further details). The baseline variables and longitudinal disease progression attributes are then used together to predict the final health outcomes of HRQoL/utility, survival, and health service resource use and cost over lifetime.
Health service resource use and cost
The model represented in Figure 1a ,b includes health service resource use, which is an addition to the list of final health outcomes included in previously reported statistical analyses. 13 COPD-related health service resource use was based on an analysis of the TORCH data from the following health service resource use categories: hospital bed days (general ward, intensive care unit), emergency room visits, and outpatient visits (hospital, physician office, home day/night). The TORCH study included 3 years of follow-up, without censoring, for every patient. The equations reported represent the yearly resource use based on the 3 years of resource use data available in TORCH. Negative binomial count data models with a log link were used for the resource counts, adjusted for the baseline variables from the TORCH study, and are reported in full in Supplemental Appendix A. Indicator variables for the treatment arm of the TORCH study were not used, so the intercept of the models (along with the rest of the coefficients) effectively represents a pooling across all treatment arms of TORCH.
Weighting predicted health service resource use in each category computed using the relevant UK unit costs for that category (unit costs, inflated to a base year of 2012, are reported in Suppl. Appendix B [Suppl. Table S8 ]) 15,17-23 enabled the annual health service costs associated with the progression of COPD to be calculated, taking into account the baseline factors as well as the central disease attributes on costs. These costs were then discounted at an annual rate of 3.5% 24 to provide the net present value of COPD costs, predicted over the lifetime of each patient who enters the model. Mapping SGRQ score to EuroQol-5 dimension (EQ-5D) utility
The previously reported statistical equations predict the patient-reported outcome of the SGRQ-C, as collected in ECLIPSE. 13 However, for health economic modeling, a cardinal utility measure of HRQoL, such as that associated with EQ-5D, is required as a basis for estimating quality-adjusted life years (QALYs). This was achieved first by converting SGRQ-C score to SGRQ Total score, as described previously, 13 based on guidance from the user manual. 15 A mapping function, estimated from data available in TORCH where both instruments had been collected, suggested the following relationship between EQ-5D and SGRQ Total score 25 :
EQ-5D50:9617 À 0:0013 3 SGRQ À 0:0001 3 SGRQ 2 10:0231 3 male:
The longitudinal survival, lung function, exacerbations, symptoms, and exercise capacity equations included a time trend term in the regression models. 13 These equations were projected from the observed 3 years of the ECLIPSE study to estimate lifetime outcomes. Weighting-predicted survival each year by predicted EQ-5D gave a yearly estimate of quality-adjusted survival. Summing this over the lifetime of the model and applying a discount rate of 3.5% 24 gave the net present value of estimated QALYs over the lifetime of each patient entering the model.
Model Validation
The conceptualization of the new model of COPD disease progression was reported separately 12 
Cohort Estimation and Baseline Values
To generate predicted values for the ECLIPSE cohort (employing the statistical equations reported previously 13 and the resource use equations described above and reported in the Supplemental Appendix), the baseline characteristics of each of the 1957 patients forming the estimation sample of ECLIPSE were entered into the model. The resulting predictions of lifetime health service resource use cost and QALYs for each patient were estimated based on the predicted symptoms, exacerbations, lung function, and exercise capacity as presented in Figure 1a ,b. The distribution of costs and QALYs gave an indication of the heterogeneity of outcomes predicted by the model for cohort members with different characteristics. Averaging these estimates gave the predicted average lifetime costs and QALYs for the entire ECLIPSE cohort. There has been much interest in the role of past exacerbations as a predictor of future exacerbations. 26 Therefore, we have performed subgroup analyses to explore the importance of exacerbation history in the model as a prognostic variable.
Probabilistic Sensitivity Analysis
Uncertainty in each of the statistical model equations was represented through the variance covariance matrix of the estimated statistical model. This represents not only the variance of the estimated coefficients but also their covariance, allowing the probabilistic sensitivity analysis to account for both the parameter uncertainty and the potential correlation between input parameters. The method of Cholesky decomposition 27 was employed to correlate draws from a multivariate normal distribution of parameter values within each equation. This uncertainty was propagated through the model structure to estimate the uncertainty associated with the lifetime cost and QALY predictions of the model. This estimation of uncertainty is conditional on the individual characteristics of the patient and provides a patient-characteristic specific estimate of uncertainty in the predictions of the model. Heterogeneity is represented by the differing predictions for patients with different characteristics and is illustrated in the model using history of an exacerbation as a subgroup of interest, reflecting recent interest in a possible high exacerbation phenotype among COPD patients. Uncertainty in the model predictions is estimated given a set of patient characteristics such that uncertainty estimates are nested within the estimated heterogeneity. Table 1 shows the predicted results for each of the 3 years of the model for overall survival, disease progression attributes, and HRQoL. Figure 2a compares the predicted and observed survival for the 3 years of ECLIPSE. For FEV 1 , the estimated annual decline based on the ECLIPSE study has previously been reported as 33 mL (95% CI, [29] [30] [31] [32] [33] [34] [35] [36] [37] . 28 This is a relatively good fit with the estimated 27-mL annual decline estimated using the statistical equations that control for changes in other predictors of the disease progression attributes, 13 which becomes a 39-mL annual decline once the effects of moderate and severe exacerbations on FEV 1 are taken into account. Figure 2 also shows the observed and predicted values of percent predicted FEV 1 , moderate and severe exacerbations, symptoms, and HRQoL as measured by SGRQ Total score over the first 3 years of the model. The annual rate of total and severe exacerbations in the first year was previously reported as 1.21 and 0.22, respectively (CIs not reported). 26 This is comparable with 1.20 and 0.21 total and severe exacerbations per patient as predicted by the model. The annual decline in 6MWD for ECLIPSE patients was previously reported as 5.7 m (CIs not reported). 29 This is comparable with the 7.8-m annual decline estimated using the statistical equation, 13 which becomes an annual decline of 6.1 m when the effects of lung function, exacerbations, and symptoms over time are taken into account. The predicted SGRQ-C values were significantly different from the observed values in years 2 and 3. In general terms, the predictions of lung function and severe exacerbations were closer to the reported values for ECLIPSE than the predicted values for moderate exacerbations, symptoms, mortality, and quality of life.
RESULTS
Validating Model Projections at 3 Years
Heterogeneity of Costs and QALYs
Averaging over the predicted cost and QALY outcomes for the different patients within the ECLIPSE cohort gives an estimated lifetime cost of £25,214 (undiscounted) and £20,318 (discounted) and lifetime QALYs of 6.45 (undiscounted) and 5.24 (discounted) per patient in the ECLIPSE cohort. As described above, results from the model predictions are individualized based on the characteristics of the patient. However, the average per-patient lifetime costs and QALYs presented above mask the differences in the individual patient predictions. Figure 3 shows the joint distribution of predicted lifetime costs and QALYs for the 1957 patients from ECLIPSE, based on the data for those patients with a full data set available at baseline. In addition to the joint distribution on the cost-effectiveness plane, the univariate distributions for lifetime cost and QALYs are shown. As is commonly observed in practice, both health outcomes and costs are predicted to be positively skewed across patients. The correlation between predicted cost and QALY outcomes was modest, with an estimated correlation coefficient of 0.08, reflecting the competing influences that patients who live longer generally incur more costs, but that those with shorter survival are generally in more advanced stages of disease and cost more. Figure 4 shows the projected survival (undiscounted, Figure 4a ) and total accumulated cost (discounted, Figure 4b ) for an average patient in ECLIPSE within 2 subgroups: those with no history of exacerbation at study entry and those with a history of exacerbation at study entry. It is clear from the 2 panels of Figure 4 that history of exacerbation is associated with lower survival and increased cost over the lifetime of the patient.
Lifetime Projections by History of Exacerbation
Analysis of Uncertainty
A probabilistic sensitivity analysis was employed to explore the uncertainty in lifetime costs and QALYs for 2 types of patient based on ECLIPSE equations: those with no history of exacerbation at study entry and those with a history of exacerbation at study entry. These results are presented on the cost-effectiveness plane in Figure 5 . Summary results of the uncertainty analysis reveal uncertainty in estimates for these 2 patient subgroups: the additional QALYs was 0.48 for the no-exacerbation history group (95% CI, -1.15 to 1.91) with the additional costs for the exacerbation group being £4961 (95% CI, -£491 to £11,607) more expensive.
DISCUSSION
We have presented a new model of COPD that was constructed from an initial conceptualization of the disease and validated using the data source that was used to estimate model parameters. To date, most other models have employed state transition models based on percent predicted FEV 1 as a measure of disease progression. In the present analysis, we have broadened the definition of COPD progression to incorporate exacerbations, lung function, exercise capacity, and symptoms as central attributes of the condition. This approach is consistent with a more contemporary definition of disease severity based on the multifactorial understanding of COPD. [7] [8] [9] Although all previous models have incorporated exacerbations, they have tended to do so based on the consideration that this is a state that is dependent only on percent predicted FEV and without estimating the relationship between exacerbations and disease progression. One exception is the Dutch population model of COPD, where each exacerbation causes the FEV 1 % predicted to decline with 0.19% (95% CI, 0.092-0.29). 30 The implementation of the model is also novel. The use of a linked-equations approach is not commonly used in HTA modeling, although it has clear links to the epidemiological literature of causal modeling. The approach was made possible through the ECLIPSE study, which provided a rich source of data from which to estimate the interconnected relationships that defined our conceptual model. Furthermore, we were able to show that the model was able to predict back the outcomes of the ECLIPSE study-although the less than perfect fit in some cases was due to the fact that the structure imposed by the conceptual model required all equations to be fit in a particular way, with particular interdependencies. For example, the conceptual model suggested that exacerbation history was expected to affect lung function, 12 while lung function was expected in turn to affect the risk of exacerbation, and the empirical results confirmed this to be the case. 13 The resulting model estimated both jointly, adding structure to the analysis. Unrestricted prediction models of each outcome (independently), which do not represent those interdependencies, would undoubtedly have provided a better fit to the data on each occasion but would lose the richness of the interdependencies that the current model is able to estimate. It is these interdependencies that allow the estimation of the impact of treatment that is shown to affect a surrogate end point (e.g., symptoms and/or FEV 1 % predicted) on final outcomes.
ECLIPSE was an observational study, designed to gain a better understanding of COPD as a disease. This made it ideal in many respects for developing a new model of COPD disease progression. The purpose of developing the present model was to provide a method for estimating long-term treatment effects where new and existing treatments for COPD are observed to affect a variety of prognostic markers. We anticipate that the model is most likely to be used when treatment is shown to affect a combination of the disease progression attributes of exacerbations, lung function, exercise capacity, or symptoms. In future work, the model will also enable estimation of the cost-effectiveness of a wide range of treatment interventions, acting through different mechanisms, used for the management of COPD.
One of the features of the Galaxy COPD model is the way that it captures uncertainty in prognosis for individual patients who have different characteristics. In this way, the model is able to represent uncertainty in the predicted costs and QALY outcomes based on the estimated parameters, which include parameters describing heterogeneity between individuals. The uncertainty analysis is therefore nested within the analysis of heterogeneity, with the consequence that uncertainty can be quantified for individual patient predictions (or equivalently for homogeneous cohorts). When modeling heterogeneous cohorts, the interval estimates produced will reflect both uncertainty and heterogeneity.
The strengths of our approach include explicit documenting of an underlying conceptual model and validation of the model constructed according to best practice guidelines. 10, 11, 31 Furthermore, the model incorporates not only the effect of lung function but also exacerbations, exercise capacity, and symptoms. When combined with baseline prognostic variables, this results in a highly flexible model that can generate predicted changes in QALYs and health service resource costs associated with a wide variety of potential treatments or disease management strategies for COPD, as well as explore potential subgroup analyses. Treatment effects can be incorporated into the model in two ways. First, if there is evidence of the treatment effect on a given surrogate end point included in the model, the effect of changes to this end point on the final cost, survival, and HRQoL (QALY) outcomes can be estimated. Second, if direct evidence of the treatment effect on both surrogate and final outcomes is available, then the model can estimate the central association corrected treatment effect that acts independently of the central associations.
Nevertheless, there are limitations to the modeling approach adopted. First, the model is based on a single, albeit large, cohort study of COPD, and therefore the generalizability of the model is dependent on the generalizability of the ECLIPSE study cohort. For example, patients in ECLIPSE were largely recruited from secondary care, and although the inclusion criteria included FEV 1 \80%, the mean was 48%. The linked-equations approach to modeling is likely to be unfamiliar to many potential users of the model, and this may limit its acceptance by decision makers. For this reason, an extensive validation of the model predictions is required. An internal validation against the ECLIPSE data was presented and revealed that in seeking to predict a number of different outcomes simultaneously, the fit achieved was not as good as if a single model had been used to fit each of these outcomes independently. Nevertheless, the ability of a model to fit the data used to estimate its parameters is a necessary, but not sufficient, condition for validation. In practice, external validation (i.e., the ability of the model to predict data not used in its construction) is much more important than internal validation. In the next article of the series, we will report the ability of the model to predict outcomes in 2 large clinical trials that included COPD patients: the TORCH study 15 and the Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT) study. 32 
CONCLUSIONS
We have reported the conceptualization, implementation, and internal validation of a new form of model for COPD, which is based on a series of linked equations estimated from a longitudinal cohort study of COPD patients. This Galaxy COPD model is capable of predicting COPD outcomes for a variety of potential treatment effects on intermediate risk factors in both the short and long term. Further external validation of short-and long-term predictions of the model is required.
